Rocket Pharmaceuticals is trading 5.13% higher at $2.35, with a biotech-sector rally providing the likeliest context for the gain. - XBI was reported up 2.10% during regular trading, supporting a sector explanation without establishing the precise cause. - No clear company-specific announcement explaining the October 20 move surfaced; its scheduled healthcare conference participation is not evidence of a direct catalyst. - Goldman Sachs’ rating change was reported October 8, so it is not a new catalyst for this session.